Insulin resistance in the 21st century: new takes on an old problem—2025 Diabetes, Diabetes Care, and Diabetologia Expert Forum

Insulin resistance is a hallmark of type 2 diabetes and several other metabolic diseases. However, efforts to improve insulin resistance are hindered by the biological complexity inherent to insulin action, as well as conceptual and methodological limitations to date. In September 2025, the editors of Diabetes , Diabetes Care and Diabetologia convened an Expert Forum in advance of the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD). Participants reviewed the latest research, clarified key concepts and recommended future research priorities. Their insights were presented at a symposium during the EASD meeting and are offered in more detail here. The authors challenge the historical view of insulin resistance as a single, uniform pathophysiological condition, describing it instead as a diverse and highly plastic set of adaptive, maladaptive, acute and chronic responses that manifest differently throughout the body, in numerous biological processes, within and among individuals, and under various physiological and environmental conditions. They describe existing methods of measuring whole-body and tissue-specific insulin resistance and offer a primer on the two main insulin signalling networks. Next, they review current therapeutic options, which offer mostly indirect effects on insulin resistance, and highlight promising strategies to inform the eventual development of true insulin-sensitising agents. The authors call for continued investigation of the complex factors accounting for variability in insulin resistance, as well as pathway-specific defects, with the ultimate goal of developing targeted and more effective therapies for type 2 diabetes and the broader spectrum of cardiometabolic complications and related comorbidities.

Authors

Institutions

Publication Details

Journal
Diabetologia
Published
2026-09-28
DOI
https://doi.org/10.1007/s00125-026-06853-9
Citations
1
Primary Topic
Adipokines, Inflammation, and Metabolic Diseases
Type
article
Field-Weighted Citation Impact
4.95
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Insulin resistance in the 21st century: new takes on an old problem—2025 Diabetes, Diabetes Care, and Diabetologia Expert Forum

Martin Heni, Olga Göransson, Michael Roden, Eunhee Choi et al.
1 citations
Diabetologia
Adipokines, Inflammation, and Metabolic Diseases
4.95
article

Insulin resistance in the 21st century: new takes on an old problem—2025 Diabetes, Diabetes Care, and Diabetologia Expert Forum

Martin Heni, Olga Göransson, Michael Roden, Eunhee Choi, Lauren Marie Sparks, Karin Conde‐Knape, Sanna H. Lehtonen, Amalia Gastaldelli, Anna Krook, Patrick Schrauwen
article en
1 citations

Abstract

Insulin resistance is a hallmark of type 2 diabetes and several other metabolic diseases. However, efforts to improve insulin resistance are hindered by the biological complexity inherent to insulin action, as well as conceptual and methodological limitations to date. In September 2025, the editors of Diabetes , Diabetes Care and Diabetologia convened an Expert Forum in advance of the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD). Participants reviewed the latest research, clarified key concepts and recommended future research priorities. Their insights were presented at a symposium during the EASD meeting and are offered in more detail here. The authors challenge the historical view of insulin resistance as a single, uniform pathophysiological condition, describing it instead as a diverse and highly plastic set of adaptive, maladaptive, acute and chronic responses that manifest differently throughout the body, in numerous biological processes, within and among individuals, and under various physiological and environmental conditions. They describe existing methods of measuring whole-body and tissue-specific insulin resistance and offer a primer on the two main insulin signalling networks. Next, they review current therapeutic options, which offer mostly indirect effects on insulin resistance, and highlight promising strategies to inform the eventual development of true insulin-sensitising agents. The authors call for continued investigation of the complex factors accounting for variability in insulin resistance, as well as pathway-specific defects, with the ultimate goal of developing targeted and more effective therapies for type 2 diabetes and the broader spectrum of cardiometabolic complications and related comorbidities.

Diabetologia
University of Helsinki (FI), Lund University (SE), Columbia University Irving Medical Center (US), AdventHealth Orlando (US), Leiden University Medical Center (NL), Karolinska Institutet (SE), Düsseldorf University Hospital (DE), Universitätsklinikum Tübingen (DE), Istituto di Fisiologia Clinica (IT), Deutsches Diabetes-Zentrum e.V. (DE), University Hospital Ulm (DE), National Research Council (IT), German Center for Diabetes Research (DE), Heinrich Heine University Düsseldorf (DE), Columbia University (US), University of Tübingen (DE)
Partnerships for the goals
Openalex Percentile: Top 4%
Adipokines, Inflammation, and Metabolic Diseases
4.95
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.